Management of the post-COVID-19 condition—often referred to as long COVID—is a challenge for health-care professionals because of the heterogeneity and complexity of its clinical manifestations and the probable need for multidisciplinary management approaches.
Identification and understanding of modifiable determinants associated with manifestations of long COVID would help in the adaptation of treatment pathways for particular phenotypes.
In The Lancet Respiratory Medicine, the PHOSP-COVID Collaborative Group report the latest results from the UK-based, multicentre, prospective Post-hospitalisation COVID-19 (PHOSP-COVID) study, in which the investigators identified systemic inflammation and obesity as factors that might be associated with long COVID, representing potentially treatable traits in people with more severe post-COVID-19 symptoms. In the current report, the PHOSP-COVID Collaborative Group found increased levels of several biomarkers related to systemic inflammation and lung damage in individuals with more severe physical and mental health impairments 1 year after hospital discharge. The presence of increased levels of systemic inflammatory biomarkers (eg, cytokines) in individuals with severe acute COVID-19 has been reported previously.
Moreover, the use of anti-inflammatory agents such as corticosteroids or interleukin-6 (IL-6)-blocking agents has been found to be associated with positive outcomes in patients hospitalised with acute COVID-19. The PHOSP-COVID Collaborative Group found that long-lasting systemic inflammation was present in people with more severe symptoms of long COVID, which could provide biological plausibility for the presence of severe impairments in people with persistent symptoms after acute COVID-19—sometimes referred to as long haulers—and allow new therapeutic strategies to be applied in these patients via a personalised medicine approach. The presence of long-lasting systemic inflammation in some patients with long COVID would suggest that anti-inflammatory agents might have potential not only during the acute phase of infection, but also during the post-acute phase. However, no clinical trial has yet investigated the effects of anti-inflammatory agents in patients with long COVID. Accordingly, a pharmacological treatment strategy based on anti-inflammatory agents for individuals with severe symptoms of long COVID, combined with other therapeutic or rehabilitative approaches that might be considered for specific symptoms (eg, pain or cognitive blurring), should be considered in future research. However, several questions need to be addressed about the potential use of such agents. For example, should individuals with less severe long COVID receive anti-inflammatory agents? The current study confirmed the presence of four clusters of symptoms with different severities of mental and physical health impairment—very severe, severe, moderate–cognitive, and mild—and found that inflammatory mediators of tissue damage and repair, including IL-6, were elevated in both the very severe and the moderate–cognitive clusters compared with the mild cluster; identifying individuals who might benefit from an anti-inflammatory approach will be an important aim of future studies. Because extended use of anti-inflammatory agents often leads to side-effects, when should these agents be given after the acute phase of infection and for how long? Should anti-inflammatory agents be given when symptoms are severe, or could a preventive therapeutic approach be implemented? The results of the PHOSP-COVID study open up highly relevant questions from a clinical viewpoint.
The PHOSP-COVID Collaborative Group also found that female sex and obesity are factors associated with more severe physical and mental health impairments 1 year after hospital discharge. These results are consistent with previous reports in the medical literature that obesity and female sex are risk factors for long COVID. However, The PHOSP-COVID Collaborative Group’s findings add to the evidence base by confirming these associations in a large cohort with long-term follow-up. The association between obesity and severe long COVID might be expected because the multisystemic changes (ie, hormonal, metabolic, and a pro-inflammatory state) associated with obesity could promote the maintenance of a systemic inflammation. Therefore, management of patients with long COVID should include the promotion of healthy lifestyle habits (eg, nutrition habits and exercise) to reduce the impact of obesity. Additionally, exercise is proposed as a therapeutic strategy to be applied in patients with long COVID because it has anti-inflammatory and proimmune effects and it could lead to reduced bodyweight. Nevertheless, considering that patients with obesity are at increased risk of developing severe long COVID symptomatology, exercise and physical activity should be carefully monitored by health-care professionals.